Single Use Bioreactor Market Size, Share, and Industry Analysis By Product (Systems (Stirred-tank Bioreactors, Wave-Mixed Bioreactor, and Others), and Accessories (Single-Use Media Bags and Others)), By Cell Type (Mammalian and Microbial), By End User (Pharmaceutical & Biotechnology Companies, CROs & CDMOs, and Others), and Regional Forecast, 2026-2034

The global single use bioreactor market size was valued at USD 5.46 billion in 2025. The market is projected to grow from USD 6.41 billion in 2026 to USD 23.17 billion by 2034, exhibiting a CAGR of 17.43% during the forecast period.

The global single use bioreactor market is growing owing to increased use of biologics, cost savings, growth in advanced technology, and the development of infrastructure, hence promoting their implementation in many emerging markets.

• According to U.S. Food and Drug Administration, 1,250 Single use bioreactor installations in US biopharma were done in 2023.

Single Use Bioreactor Market Driver

Biologics demand, CDMO adoption, tech advances drive single-use bioreactors

Increasing need for biologics and biosimilars, along with monoclonal antibodies and vaccines, is leading to using single-use bioreactors more, due to their ability to handle advanced cell and gene therapies rapidly and affordably.

Switching to single-use bioreactors helps cut down on costs since the capital investment is about 42% lower than with stainless-steel reactors. Higher efficiency and flexibility are now possible for manufacturing thanks to lower requirements for SUBs, making SUBs more widely used.

Both CDMOs and CMOs are using single-use bioreactors to efficiently handle various projects and speed up the moving from one process to another. This flexibility means more drugs are now being outsourced, which in turn helps SUB technologies grow faster in the market.

Due to improvements in bioprocessing technologies, single-use bioreactors are working more efficiently and consistently, making them more attractive and used in current biotechnology environments.

Single Use Bioreactor Market Restraint

Concerns Over Extractables and Leachables, Regulatory Compliance Issues, Limitations in Large-Scale Production may Affect Market Expansion

Using plastics in single-use bioreactors seems to raise safety questions in the products being considered for extractables and leachables. Considering these issues, companies need to perform tests on these items and meet strict standards, which may weaken their belief in these products and delay their use in key bioprocesses.

Because of the ever-changing standards and guidelines, it is quite complex to comply with regulations for the single-use bioreactors, thus challenging manufacturing in these processes. Product delays in approval and market entry through regulatory hurdles may well affect the timely commercialization of new bioprocessing technologies and, in turn, slow the market growth.

Beyond nearly 6,000 liters can never be produced by single-use bioreactors. Stainless steel has welcomed various usages in large biopharmaceutical plants, impeding the movement of additive manufacturing.

Single Use Bioreactor Market Opportunity

Expansion in Emerging Markets, Integration with Bioprocessing 4.0, Development of Hybrid Facilities to Offer New Growth Avenues

Places like Asia-Pacific and Latin America are attracting more investments in the biopharmaceutical sector. With more demand for biologics and better production systems being set up, there is an increase in the use of single-use bioreactors in Asia and Africa.

Introducing Bioprocessing 4.0, such as artificial intelligence and machine learning, is helping single-use bioreactors become more optimized. Thanks to advancements in technology, SUBs are now able to produce more, make improved products, and waste less, which attracts biomanufacturers.

The increase in hybrid plants allows for both flexible and large-scale operations. With this method, manufacturers can produce items on a smaller or larger scale while keeping costs and capacity low.

Segmentation

Key Insights

The report covers the following key insights:

• Incidence of Single-Use Bioreactor Adoption, By Key Countries
• Diagnostic Statistics for Bioprocessing Efficiency and Production Capacity across Major Markets
• Major Market Drivers, Trends, and Investment Opportunities in Flexible and Contamination-Free Biomanufacturing
• Business Strategies Adopted by Key Players and Key Industry Developments (Mergers, Acquisitions, Partnerships)
• Overview: Regulatory Scenario and Government Policies Supporting Biopharmaceutical Manufacturing Innovations

Analysis by Product

Based on Product, the Single Use Bioreactor Market is subdivided into Systems (Stirred-tank Bioreactors, Wave-Mixed Bioreactor, and Others), and Accessories (Single-use media bags, and Others).

Growth in the stirred-tank bioreactors area is mainly due to their use in large-scale cell culture processes. Their ability to handle larger operations, mix ingredients quickly, and work with monitoring software helps make them preferable in these industries. Stirred-tank Bioreactors lead the market owing to their ability to scale, fit into existing processes, and be widely used in biopharmaceuticals.

The perfusion-based and small-scale uses of wave-mixed bioreactors are helping this segment to gain traction. As a result, bioreactors are great choices for vaccine manufacturing and the development of regenerative medicine due to the gentle mixing, low shear stress, and their ease of use.

Analysis by Cell Type

By Cell Type, the Single Use Bioreactor Market is fragmented into Mammalian, and Microbial.

Being first and foremost for monophasic antibodies and vaccines, the mammalian cell segment acts as an important driver of the market. There appear to be plenty of opportunities to utilize mammalian cells in therapeutic protein manufacture due to their high compatibility with single-use systems. Mammalian cells are the most preferred because of their significance in producing monoclonal antibodies and complex biologics.

The microbial cell market is developing as their enzyme, insulin, and other biologics applications are maturing. Microbial cells are an advantage to biotechnology because they grow fast and are cost-effective, being suitable for single-use bioreactors.

Analysis by End User

Based on end user, the Single Use Bioreactor Market is divided into Pharmaceutical & Biotechnology Companies, CROs & CDMOs, and Others.

The largest part of the market comes from pharmaceutical and biotechnology companies thanks to the increased demand for biologics and flexible, scalable ways to produce them. Single-use bioreactors help achieve greater efficiency and cut down on risks of both contamination and high cleaning validation needs. High biologics production and rising use of disposable devices have made pharmaceutical and biotechnology companies the main dominators.

Single-use bioreactors are being used more often by CROs and CDMOs as they allow for fast batch production and lowered costs. There is an increasing use of outsourcing for drug development and production, which leads to greater growth in different parts of the world.

Regional Analysis

Based on region, the Single Use Bioreactor Market has been studied across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

To gain extensive insights into the market, Download for Customization

While the biopharmaceutical industry in North America is about 35%, the region has a strong industry, big R&D expenditures, a strong healthcare infrastructure, and policies that allow firms to prosper and innovate.

Europe is ranked for biosimilar development because of the powerful academic and research centers that are generating new ideas. And then industry and regulators collectively streamline the approvals process, thus keeping this market of biopharmaceuticals ahead in production.

Asia-Pacific biopharmaceuticals will be fast-growing markets due to more investments in manufacturing, increased demand for biologics and similar drugs, and the government's interventions to promote bioprocessing advances and upgrade healthcare facilities.

Key Players Covered

The report includes the profiles of the following key players:

• Eppendorf SE (Germany)
• Cytiva (U.S.)
• Sartorius AG (Germany)
• Thermo Fisher Scientific Inc. (U.S.)
• Cobetter (China)
• DH Life Sciences, LLC. (U.S.)
• Avantor, Inc. (U.S.)
• bbi-biotech (Germany)
• Distek, Inc. (U.S.)

Key Industry Developments

• In March 2024, the Single-Use Production Reactor (SUPR) system was introduced by Getinge AB in 50-liter and 250-liter versions for greater duality in terms of downstream bioproduction.
• In April 2023, Ultimus single-use process container film was introduced by Merck KGaA to be used under bioprocessing conditions with severe demands on puncture resistance and extreme leakproofness.